TY - JOUR
T1 - Topical testosterone supplementation for the treatment of male hypogonadism
AU - Abadilla, Katrina A.
AU - Dobs, Adrian S.
N1 - Funding Information:
Dr Adrian Dobs declares that she has received honoraria, travel grants and research funding from pharmaceutical research sponsors including Endo Pharmaceuticals, ProStrakan, Indevus and the National Institutes of Health.
PY - 2012
Y1 - 2012
N2 - Age-related hormonal decline is gradual and less recognized in men than in women. Symptoms are oftentimes ignored and non-specific. Fatigue, lack of concentration, mood swings, decreased sexual desire, erectile dysfunction, infertility, hair loss, reduced muscle and bone mass, and weight gain are a few of the symptoms of male hypogonadism. This disorder is linked to reduction in quality of life, and poorer health outcomes as it may increase the risk for cardiovascular disease, diabetes mellitus, metabolic syndrome, Alzheimers disease and premature death. Different modalities of testosterone replacement therapy have evolved over 70 years, and sales continue to grow. Each preparation is differentiated by route of delivery, ease of use, cost and pharmacokinetics.Topicaltransdermal testosterone replacement therapy, including patches and gels, are the most modern formulations on the market. These are more expensive treatments, but yield more physiological concentrations of testosterone. Restoration of testosterone levels to the eugonadal range reverses signs and symptoms of hypogonadism, except for infertility, and may alleviate co-morbidities associated with hypogonadism. Patient understanding of and compliance with both treatment and monitoring are of utmost importance to achieve clinical success with maximum benefit and minimum risk. The aim of our review is to summarize the indications, contraindications, benefits and risks of testosterone replacement therapy as they relate to transdermal administration. Further, we compare the various testosterone preparations, focusing on the newest topicaltransdermal routes of administration that are currently available.
AB - Age-related hormonal decline is gradual and less recognized in men than in women. Symptoms are oftentimes ignored and non-specific. Fatigue, lack of concentration, mood swings, decreased sexual desire, erectile dysfunction, infertility, hair loss, reduced muscle and bone mass, and weight gain are a few of the symptoms of male hypogonadism. This disorder is linked to reduction in quality of life, and poorer health outcomes as it may increase the risk for cardiovascular disease, diabetes mellitus, metabolic syndrome, Alzheimers disease and premature death. Different modalities of testosterone replacement therapy have evolved over 70 years, and sales continue to grow. Each preparation is differentiated by route of delivery, ease of use, cost and pharmacokinetics.Topicaltransdermal testosterone replacement therapy, including patches and gels, are the most modern formulations on the market. These are more expensive treatments, but yield more physiological concentrations of testosterone. Restoration of testosterone levels to the eugonadal range reverses signs and symptoms of hypogonadism, except for infertility, and may alleviate co-morbidities associated with hypogonadism. Patient understanding of and compliance with both treatment and monitoring are of utmost importance to achieve clinical success with maximum benefit and minimum risk. The aim of our review is to summarize the indications, contraindications, benefits and risks of testosterone replacement therapy as they relate to transdermal administration. Further, we compare the various testosterone preparations, focusing on the newest topicaltransdermal routes of administration that are currently available.
KW - Buccal
KW - Hypogonadism
KW - Oral
KW - Subdermal
KW - Testosterone
KW - Testosterone-cipionate
KW - Testosterone-enantate
KW - Testosterone-undecanoate
KW - Topical
KW - Transdermal
UR - http://www.scopus.com/inward/record.url?scp=84864708706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864708706&partnerID=8YFLogxK
U2 - 10.2165/11635620-000000000-00000
DO - 10.2165/11635620-000000000-00000
M3 - Review article
C2 - 22867042
AN - SCOPUS:84864708706
SN - 0012-6667
VL - 72
SP - 1591
EP - 1603
JO - Drugs
JF - Drugs
IS - 12
ER -